Skip to content
Screener

Solid Biosciences Inc. SLDB Total Non-Current Liabilities

Total Non-Current Liabilities at other companies

Wave Life Sciences logo
Wave Life SciencesWVE
$53.99M+203%
uniQure logo
uniQureQURE
$577.71M+5.4%

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.4M-37.6%
Net income-$54.8M-38.8%
EPS (diluted)-$0.38+9.5%

Balance sheet

See full
Cash & equivalents$159.4M+14.7%
Total debt$20.2M-12.6%
Total equity$374.1M+44.8%
Total assets$420.6M+36.4%

Cash flow

See full
Operating cash flow-$52.6M-40.6%
CapEx$150.0K-60.2%
Free cash flow-$52.7M-39.6%

Valuation

See full
Market cap$917.85M+94.8%
Enterprise value$778.61M+119%

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-65.5%-2.5pp
Debt / equity0.1×0.0×
Current ratio13.8×+4.5×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesNoncurrent.

The source filing: Solid Biosciences Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-337935
Line itemJune 30, 2026December 31, 2025
Total current liabilities28,58433,472
Non-current liabilities:
Operating lease liabilities, net of current portion17,92119,058
Total non-current liabilities17,92119,058
Total liabilities46,50552,530
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025; no shares issued or outstanding at June 30, 2026 and December 31, 2025——

Item 1. Financial Statements (unaudited)

FAQ

What is Solid Biosciences Inc.'s total non-current liabilities?
Solid Biosciences Inc. (SLDB) reported total non-current liabilities of $17.92M in Q2 2026.
How has Solid Biosciences Inc.'s total non-current liabilities changed year-over-year?
Solid Biosciences Inc.'s total non-current liabilities decreased by 11.1% year-over-year, from $20.16M to $17.92M.
What is the long-term trend for Solid Biosciences Inc.'s total non-current liabilities?
Over 2 years (2023 to 2025), Solid Biosciences Inc.'s total non-current liabilities has grown at a -10.8% compound annual growth rate (CAGR), from $23.94M to $19.06M.
What does total non-current liabilities mean?
The sum of all long-term obligations due beyond one year — long-term debt, lease liabilities, pension obligations, and deferred items.

Ask your AI about Solid Biosciences Inc.'s total non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude